S&P 500   4,319.11 (+0.51%)
DOW   34,242.81 (+0.97%)
QQQ   334.33 (+0.38%)
AAPL   173.59 (+0.23%)
MSFT   293.90 (+0.15%)
META   180.79 (-0.06%)
GOOGL   122.28 (+0.16%)
AMZN   146.28 (+2.17%)
TSLA   931.82 (+0.42%)
NVDA   190.91 (+0.31%)
NIO   21.00 (-1.41%)
BABA   93.49 (-0.75%)
AMD   100.87 (-0.14%)
MU   64.47 (-0.36%)
T   18.65 (+1.41%)
CGC   3.88 (+1.57%)
F   16.66 (+2.08%)
GE   81.02 (+1.52%)
DIS   126.25 (+1.60%)
AMC   26.00 (+7.39%)
PYPL   102.92 (+1.39%)
PFE   50.16 (+0.82%)
NFLX   248.91 (-0.08%)
S&P 500   4,319.11 (+0.51%)
DOW   34,242.81 (+0.97%)
QQQ   334.33 (+0.38%)
AAPL   173.59 (+0.23%)
MSFT   293.90 (+0.15%)
META   180.79 (-0.06%)
GOOGL   122.28 (+0.16%)
AMZN   146.28 (+2.17%)
TSLA   931.82 (+0.42%)
NVDA   190.91 (+0.31%)
NIO   21.00 (-1.41%)
BABA   93.49 (-0.75%)
AMD   100.87 (-0.14%)
MU   64.47 (-0.36%)
T   18.65 (+1.41%)
CGC   3.88 (+1.57%)
F   16.66 (+2.08%)
GE   81.02 (+1.52%)
DIS   126.25 (+1.60%)
AMC   26.00 (+7.39%)
PYPL   102.92 (+1.39%)
PFE   50.16 (+0.82%)
NFLX   248.91 (-0.08%)
S&P 500   4,319.11 (+0.51%)
DOW   34,242.81 (+0.97%)
QQQ   334.33 (+0.38%)
AAPL   173.59 (+0.23%)
MSFT   293.90 (+0.15%)
META   180.79 (-0.06%)
GOOGL   122.28 (+0.16%)
AMZN   146.28 (+2.17%)
TSLA   931.82 (+0.42%)
NVDA   190.91 (+0.31%)
NIO   21.00 (-1.41%)
BABA   93.49 (-0.75%)
AMD   100.87 (-0.14%)
MU   64.47 (-0.36%)
T   18.65 (+1.41%)
CGC   3.88 (+1.57%)
F   16.66 (+2.08%)
GE   81.02 (+1.52%)
DIS   126.25 (+1.60%)
AMC   26.00 (+7.39%)
PYPL   102.92 (+1.39%)
PFE   50.16 (+0.82%)
NFLX   248.91 (-0.08%)
S&P 500   4,319.11 (+0.51%)
DOW   34,242.81 (+0.97%)
QQQ   334.33 (+0.38%)
AAPL   173.59 (+0.23%)
MSFT   293.90 (+0.15%)
META   180.79 (-0.06%)
GOOGL   122.28 (+0.16%)
AMZN   146.28 (+2.17%)
TSLA   931.82 (+0.42%)
NVDA   190.91 (+0.31%)
NIO   21.00 (-1.41%)
BABA   93.49 (-0.75%)
AMD   100.87 (-0.14%)
MU   64.47 (-0.36%)
T   18.65 (+1.41%)
CGC   3.88 (+1.57%)
F   16.66 (+2.08%)
GE   81.02 (+1.52%)
DIS   126.25 (+1.60%)
AMC   26.00 (+7.39%)
PYPL   102.92 (+1.39%)
PFE   50.16 (+0.82%)
NFLX   248.91 (-0.08%)
NASDAQ:FATE

Fate Therapeutics - FATE Stock Forecast, Price & News

$33.68
-2.38 (-6.60%)
(As of 08/16/2022 02:16 PM ET)
Add
Compare
Today's Range
$32.81
$36.10
50-Day Range
$17.78
$36.06
52-Week Range
$17.10
$91.90
Volume
70,111 shs
Average Volume
1.36 million shs
Market Capitalization
$3.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.42

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
122.9% Upside
$75.42 Price Target
Short Interest
Bearish
23.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.34mentions of Fate Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.40) to ($4.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

750th out of 1,124 stocks

Biological Products, Except Diagnostic Industry

119th out of 176 stocks

FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Analysts Set New Price Targets

Several analysts have issued reports on FATE shares. Oppenheimer cut their target price on shares of Fate Therapeutics from $135.00 to $90.00 in a research note on Thursday, August 4th. Robert W. Baird initiated coverage on shares of Fate Therapeutics in a research note on Thursday, June 2nd. They issued a "neutral" rating and a $28.00 price target on the stock. Piper Sandler dropped their price target on shares of Fate Therapeutics from $113.00 to $71.00 and set an "overweight" rating on the stock in a research note on Monday, May 23rd. Needham & Company LLC initiated coverage on shares of Fate Therapeutics in a research note on Thursday, July 28th. They issued a "hold" rating on the stock. Finally, BMO Capital Markets raised shares of Fate Therapeutics from a "market perform" rating to an "outperform" rating and dropped their price target for the stock from $50.00 to $47.00 in a research note on Monday, July 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Fate Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $75.42.

Fate Therapeutics Stock Up 6.6 %

FATE Stock traded up $2.24 during mid-day trading on Monday, reaching $36.06. 1,623,514 shares of the stock traded hands, compared to its average volume of 1,473,188. Fate Therapeutics has a 52 week low of $17.10 and a 52 week high of $91.90. The business has a 50-day moving average of $27.90 and a two-hundred day moving average of $31.18. The firm has a market capitalization of $3.50 billion, a PE ratio of -13.10 and a beta of 1.62.

Insider Buying and Selling at Fate Therapeutics

In other Fate Therapeutics news, insider Mark Plavsic sold 3,719 shares of the company's stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $24.61, for a total transaction of $91,524.59. Following the completion of the sale, the insider now directly owns 127,123 shares in the company, valued at $3,128,497.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Mark Plavsic sold 3,719 shares of the stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $24.61, for a total value of $91,524.59. Following the completion of the sale, the insider now owns 127,123 shares in the company, valued at $3,128,497.03. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO J Scott Wolchko sold 30,000 shares of the stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $32.88, for a total transaction of $986,400.00. Following the completion of the sale, the chief executive officer now owns 431,546 shares of the company's stock, valued at approximately $14,189,232.48. The disclosure for this sale can be found here. Insiders sold 53,082 shares of company stock worth $1,646,106 over the last ninety days. Company insiders own 17.34% of the company's stock.

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

Fate Therapeutics (NASDAQ:FATE) PT Lowered to $90.00
Fate Therapeutics: Q2 Earnings Insights
Expert Ratings for Fate Therapeutics
Tuesday's ETF Movers: ARKK, OIH
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings
8/03/2022
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$75.42
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+123.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

Net Income
$-212,150,000.00
Net Margins
-371.73%
Pretax Margin
-371.73%

Debt

Sales & Book Value

Annual Sales
$55.85 million
Book Value
$7.11 per share

Miscellaneous

Free Float
80,180,000
Market Cap
$3.27 billion
Optionable
Optionable
Beta
1.62














FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FATE shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2022?

12 brokerages have issued 12 month target prices for Fate Therapeutics' stock. Their FATE share price forecasts range from $28.00 to $115.00. On average, they predict the company's share price to reach $75.42 in the next twelve months. This suggests a possible upside of 109.1% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2022?

Fate Therapeutics' stock was trading at $58.51 at the start of the year. Since then, FATE stock has decreased by 38.4% and is now trading at $36.06.
View the best growth stocks for 2022 here
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) posted its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.07. The biopharmaceutical company earned $18.55 million during the quarter, compared to analyst estimates of $13.42 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 40.37% and a negative net margin of 371.73%.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.87%), State Street Corp (5.43%), Artal Group S.A. (2.68%), Pictet Asset Management SA (2.17%), JPMorgan Chase & Co. (2.06%) and FMR LLC (1.46%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $36.06.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $3.50 billion and generates $55.85 million in revenue each year. The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Fate Therapeutics have?

The company employs 449 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.